微信关注
China
Total item
Cart Subtotal
￥ 0.00 “Akt Inhibitor”的搜索结果
-
KRAS G12C inhibitor 16
Catalog No. A18444 KRAS G12C inhibitorKRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 39, has an IC50 of 97 nM. 了解更多 -
KRAS G12C inhibitor 15
Catalog No. A18447 KRAS G12C inhibitorKRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM. 了解更多 -
PARP14 inhibitor H10
Catalog No. A18616 PARP14 抑制剂PARP14 inhibitor H10, compound H 10, is a selective inhibitor against PARP14 (IC50=490 nM), over other PARPs (??24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis. 了解更多 -
BRD4 Inhibitor-10
Catalog No. A18679 BRD4-BD1 inhibitorBRD4 Inhibitor-10 is a potent BRD4-BD1 inhibitor extracted from patent WO2015022332A1, Compound II-25, has an IC50 of 8 nM. 了解更多 -
KRAS G12C inhibitor 5
Catalog No. A18840 KRas G12C inhibitorKRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147. 了解更多 -
Tuberculosis inhibitor 1
Catalog No. A18906 trypanosoma brucei growth inhibitorTuberculosis inhibitor 1 is a potent and non-cytotoxic trypanosoma brucei growth inhibitor with an EC50 of 5 nM. 了解更多 -
CA inhibitor 1
Catalog No. A18928 HIV capsid inhibitorCA inhibitor 1 (GS-6207 analog) is a potent HIV capsid inhibitor for HIV inhibition. 了解更多 -
NaV1.7 inhibitor-1
Catalog No. A18933 NaV 1.7 inhibitorNaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5. 了解更多 -
PKC-theta inhibitor 1
Catalog No. A18966 PKCθ inhibitorPKC-theta inhibitor 1 is the PKCθ inhibitor with an Ki value of 6 nM, inhibits IL-2 production in vivo with an IC50 of 0.19 μM. 了解更多 -
KRAS G12C inhibitor 13
Catalog No. A19041 KRAS G12C inhibitorKRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30. 了解更多 -
Syncytial Virus Inhibitor-1
Catalog No. A19053 RSV fusion inhibitorSyncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively. 了解更多 -
TDP1 Inhibitor-1
Catalog No. A19072 TDP1 inhibitorTDP1 Inhibitor-1 is a potent Tyrosyl-DNA Phosphodiesterase 1 (TDP1) inhibitor with an IC50 of 7 μM. 了解更多 -
FadD32 Inhibitor-1
Catalog No. A19086 FadD32 inhibitorFadD32 Inhibitor-1 is a potent FadD32 inhibitor with anti-tubercular activity. 了解更多 -
ITK inhibitor 2
Catalog No. A19096 ITK inhibitorITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC50 of 2 nM. 了解更多 -
LIN28 inhibitor LI71
Catalog No. A19107 LIN28 inhibitorLIN28 inhibitor LI71 is a potent and cell-permeable LIN28 inhibitor, which abolishes LIN28-mediated oligouridylation with an IC50 of 7 uM. 了解更多 -
HIV-1 inhibitor-3
Catalog No. A19110 HIV infection inhibitorHIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927. 了解更多 -
EMT inhibitor-2
Catalog No. A18568 EMT inhibitorEMT inhibitor-2 inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively. 了解更多 -
FGFR1/DDR2 inhibitor 1
Catalog No. A18716 FGFR1/DDR2 inhibitorFGFR1/DDR2 inhibitor 1 is an inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM, 108.4 nM and 3.2 nM for FGFR1, KG-1, and DDR2, respectively. 了解更多 -
RAD51 Inhibitor B02
Catalog No. A18334 RAD51 inhibitorAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM. 了解更多 -
Tie2 kinase inhibitor
Catalog No. A10932 -
TC-S 7010 (Aurora A Inhibitor I)
Catalog No. A10100 Aurora A 抑制剂TC-S 7010 (Aurora A Inhibitor I)是Aurora A激酶（AurA）的有效和选择性抑制剂，IC50值为3.4 nM（Aurora A），对Aurora B具有极高的选择性1000倍； 用于研究Aurora A激酶的细胞作用的有用工具化合物。 了解更多 -
Afuresertib
Catalog No. A16392 -
ARQ-092 (Miransertib)
Catalog No. A16286 -
Akt1 and Akt2-IN-1
Catalog No. A16285 AKT 1/2 抑制剂Akt1 and Akt2-IN-1是Akt1（IC50 = 3.5 nM）和Akt2（IC50 = 42 nM）的变构抑制剂，具有有效且平衡的活性。 了解更多 -
Tomatidine
Catalog No. A16233 -
TIC10
Catalog No. A15903 -
SC 66
Catalog No. A12081 -
GSK2141795 (Uprosertib, GSK795)
Catalog No. A15809 Akt 抑制剂GSK2141795 (Uprosertib,GSK795)结合并抑制Akt的活性，这可能导致PI3K/Akt信号传导途径的抑制和肿瘤细胞的增殖以及肿瘤细胞凋亡的诱导。 了解更多 -
AT7867 2HCl
Catalog No. A15006 Akt 抑制剂AT7867 dihydrochloride是一种有效的ATP竞争性Akt1/2/3和p70S6K/PKA抑制剂，IC50分别为32 nM/17 nM/47 nM和85 nM/20 nM，在AGC激酶家族之外几乎没有活性。 了解更多 -
Afuresertib HCl
Catalog No. A13030 AKT 抑制剂?Afuresertib HCl，也称为GSK2110183，是具有潜在抗肿瘤活性的丝氨酸/苏氨酸蛋白激酶Akt（蛋白激酶B）的生物利用抑制剂。它结合并抑制Akt的活性，这可能导致PI3K/Akt信号传导途径的抑制和肿瘤细胞的增殖以及肿瘤细胞凋亡的诱导.PI3K/Akt信号传导途径的激活通常与肿瘤发生有关，PI3K/Akt信号传导失调可能有助于肿瘤对多种抗肿瘤药的耐药性。 了解更多 -
Miltefosine
Catalog No. A14138 -
TIC10 isomer
Catalog No. A12720 -
Triciribine
Catalog No. A13210 -
GDC-0068 (Ipatasertib, RG-7440)
Catalog No. A11246 Akt 抑制剂GDC-0068 (Ipatasertib,RG-7440)是一种选择性的，具有ATP竞争性的pan-Akt抑制剂，在无细胞试验中，其靶向Akt1、2和3的IC50值分别为5、18和8 nM。 了解更多 -
A-443654
Catalog No. A11287 -
Triciribine phosphate (NSC-280594)
Catalog No. A11033 AKT 抑制剂Triciribine phosphate是一种DNA synthesis抑制剂，也抑制PC3细胞系中的Akt和CEM-SS，H9，H9IIIB，U1细胞中的HIV-1，IC50分别为130 nM和20 nM；对PI3K/PDK1没有抑制作用；作用于缺乏腺苷激酶的细胞，活性降低5000 了解更多 -
PHT-427
Catalog No. A11032 -
3-Hydroxyanthranilic acid
Catalog No. A22292 immunomodulatory agent3-Hydroxyanthranilic Acid (3-HAA, 3-HANA), a tryptophan metabolite, has an immunomodulatory effect that may result from inhibition of PI3K/Akt/mTOR and NF-κB activity, thereby decreasing the production of pro-inflammatory mediators. 了解更多 -
Loureirin A
Catalog No. A22313 flavonoidLoureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity. 了解更多
联系我们
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
Not your Region? View all Distributors
ADOOQ 产品质量保证
We promise all products to perform as described.